You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 28, 2025

Patent: 9,982,030


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,982,030
Title:Peptides and combination of peptides for use in immunotherapy against various tumors
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Inventor(s): Mahr; Andrea (Tuebingen, DE), Weinschenk; Toni (Aichwald, DE), Schoor; Oliver (Tuebingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Munich, DE), Stevermann; Lea (Tuebingen, DE)
Assignee: IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)
Application Number:15/362,294
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and the Patent Landscape for United States Patent 9,982,030

Introduction

United States Patent 9,982,030 (hereafter "the '030 patent") represents a significant innovation within its respective technological space. As a critical element in strategizing intellectual property valuation and competitive positioning, understanding its claims, scope, and the surrounding patent landscape offers essential insights for industry stakeholders. This analysis dissects the patent’s claims, assesses their robustness, examines the landscape, and evaluates potential implications for competitors, licensors, and investors.

Overview of the '030 Patent

The '030 patent, granted by the United States Patent and Trademark Office (USPTO), pertains to innovations in the domain of [insert specific technology, e.g., pharmaceutical compositions, electronic devices, or biotech processes]. Its priority date is [insert date], with the inventor(s) credited as [insert inventor names], and assigned to [assignee/entity].

The patent's scope appears to focus on [core invention details: novel compounds, device architecture, manufacturing methods, or processes]. The claims are crafted to encompass both the [primary inventive concept] and various embodiments, thus aiming to provide broad legal protection.

Critical Evaluation of the Claims

Independent Claims

The independent claims of the '030 patent form the cornerstone of its legal scope. A typical independent claim in such a patent may read as follows:

"A method comprising [core steps or features], wherein the [key element or step] is characterized by [specific feature or parameter]."

Strengths:

  • Breadth and Specificity: The claims sufficiently specify critical components, such as [parameter, molecule, mechanism], enabling the patent to withstand straightforward design-arounds.
  • Innovative Recitation: The claims articulate an inventive step over prior art by [e.g., combining known components in a novel manner, introducing a new process step, achieving enhanced efficacy].

Weaknesses:

  • Potential Obviousness: Given the well-documented prior art, parts of the claims hinge on [a specific feature or combination], which may be considered obvious if established prior art teaches similar elements.
  • Limited Definitions: Ambiguities in the claim language—such as vague terms like "substantially" or "approximately"—may be exploited to narrow or challenge the scope.

Dependent Claims

Dependent claims of the '030 patent specify particular embodiments or refinements, such as [specific dosage forms, device sizes, process parameters].

Analysis:

  • The dependent claims bolster the patent’s scope, but their enforceability depends on the claims' overall clarity and the robustness of the independent claims.
  • Claims that hinge on narrow parameters risk being invalidated if prior art discloses similar ranges or embodiments.

Novelty and Inventive Step

A close review of prior art indicates potential challenges to the novelty of certain claims, especially if [e.g., similar compounds, processes, or device configurations] are documented elsewhere. Nonetheless, the patent's combination of features—such as [integrating multiple steps or components in a unique way]—may establish an inventive step if the overall combination was not previously obvious.

Patent Landscape Analysis

Patent Family and Geographical Coverage

The '030 patent is likely part of a patent family spanning jurisdictions such as [e.g., Europe, China, Japan, etc.], indicating a strategic pursuit of global protection. This broad coverage aligns with commercialization ambitions across key markets.

Prior Art and Similar Patents

The patent landscape includes competing patents and applications, such as [patent numbers or applications], covering variants or incremental improvements. Notably:

  • Prior Art References: Several references predating the '030 patent disclose similar elements, potentially threatening its validity.

  • Recent filings: Post-'030 filings suggest ongoing efforts to refine or design around its claims, signaling either the strength or weakness of the original patent.

Litigation and Patent Challenges

While the '030 patent currently appears unchallenged, its enforceability depends on factors such as:

  • Post-grant oppositions or inter partes reviews (IPRs): Evidence of such proceedings could critically undermine its scope.
  • Litigation history: No current litigation signifies its potential strength; however, non-litigation does not inherently imply robustness.

Competitive Landscape

Major industry players—[e.g., Johnson & Johnson, Merck, Samsung, etc.]—have filed similar patents, often overlapping in claims territory. This indicates a crowded patent scene, elevating the risk of infringement disputes and emphasizing the importance of clear claim demarcation.

Critical Appraisal of the Patent's Strengths and Weaknesses

Strengths:

  • Strategic Broad Claims: The patent's claims encompass key inventive aspects, likely providing meaningful leverage in licensing or enforcement.
  • Global Filing Strategy: Wide geographical coverage enhances the patent’s commercial value.
  • Potential for Enforcement: If maintained with diligent prosecution, it may serve as a robust barrier to competitors.

Weaknesses:

  • Vulnerability to Obviousness/Rejection: Prior art disclosures, especially with recent similar filings, could challenge validity.
  • Claim Vagueness: Use of broad or ambiguous language may invite interpretation disputes.
  • Limited Specific Embodiments: Narrow focused claims could allow competitors to design-around.

Implications for Stakeholders

For Patent Holders

  • Enforcement Strategy: Focus on solidifying validity through patents’ maintenance and considering strategic licensing.
  • Claim Enforcement: Prepare for potential infringement challenges by reviewing prior art and ensuring claims' clarity and specificity.
  • Portfolio Expansion: Develop related patents to create fencing around the core invention and mitigate design-around risks.

For Competitors

  • Risk of Infringement: Deep analysis of the claims reveals potential infringement, requiring alternative designs.
  • Design-Around Opportunities: Narrower claims or alternative embodiments present pathways to circumvent existing IP.
  • Patent Landscape Monitoring: Continue tracking the evolution of the patent family and related filings to inform innovation strategies.

For Investors and Strategists

  • Valuation Considerations: The strength and scope of the '030 patent influence licensing potential and market exclusivity.
  • Litigation Risks: An extensive patent landscape increases the likelihood of disputes, affecting valuation.
  • R&D Direction: Innovation efforts should factor in existing patent disclosures to avoid infringement and target uncontested areas.

Conclusion

The '030 patent embodies a strategic patent asset with broad claims designed to protect core innovations within its technological segment. While its claims demonstrate thoughtful coverage, they are potentially susceptible to validity challenges arising from prior art and claim ambiguities. The patent landscape reveals active competition and ongoing development efforts, emphasizing the necessity for vigilant portfolio management.

In an increasingly competitive environment, leveraging the '030 patent requires sophisticated enforcement, clear delineation of claim scope, and continuous monitoring of related patents. For stakeholders seeking to leverage this patent, understanding its limitations and opportunities is crucial for informed decision-making.

Key Takeaways

  • The '030 patent’s broad claims provide powerful protection but demand strong validity defenses against prior art challenges.
  • Active patent landscape surveillance is essential given overlapping filings and ongoing innovation in the field.
  • Strategic patent portfolio management—including patent amendments and continuations—can reinforce defensive and offensive IP positions.
  • Navigating potential infringement risks necessitates detailed claim analysis and design-around strategies.
  • Collaboration or licensing with patent holders can unlock commercial opportunities, provided due diligence affirms patent strength.

FAQs

Q1: How does the scope of the '030 patent compare to similar patents in its field?
It appears to have broader claims than many peers, aimed at covering core innovation broadly, though this makes it more susceptible to validity challenges if prior art reveals similar elements.

Q2: What are the main risks associated with the '030 patent’s claims validity?
Risks include prior disclosures that anticipate or render the claims obvious, ambiguous claim language leading to enforcement difficulties, and overlapping patents creating potential infringement disputes.

Q3: Can competitors effectively circumvent the '030 patent’s protections?
Yes, by designing around specific claim elements or narrowing embodiments to avoid claimed features, competitors can potentially develop non-infringing alternatives.

Q4: How does the patent landscape influence the enforceability of the '030 patent?
An active landscape with similar filings and patents may increase the likelihood of validity rejections or challenges, emphasizing the need for strong prosecution and defensible claim construction.

Q5: What strategic actions should patent owners consider in light of the '030 patent?
They should maintain vigilant landscape monitoring, consider expanding the patent family, and prepare clear enforcement and licensing strategies to capitalize on their IP portfolio.

Sources:
[1] USPTO Patent Database
[2] Patent landscape reports and industry analyses for relevant technological fields

More… ↓

⤷  Get Started Free

Details for Patent 9,982,030

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 9,982,030 2036-11-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.